Make the FDA approve GLP-1 agonist medications for patients with IIH--NOW!!!
0 have signed. Let’s get to 1,000!
People with Idiopathic Intracranial Hypertension (IIH) have very few options for treatment. IIH is a condition that occurs when pressure inside the skull increases for no obvious reason. Many of its symptoms mimic a brain tumor. Without treatment, people can blind and may go into a coma (if the csf pressure gets high enough). As for medication options, there are few.Diamox is a drug that some patients can't take because they are allergic to it. Some patients experience severe side-effects from Diamox and Topomax and can't take them. Some patients also don't get enough relief with either drug. When medication options fail, there are limited surgical options, two of the most popular options being shunts and stents, both can come with extreme complications which include death. Patients who have IIH need more options for treatment, and we need it NOW. We can't wait for the FDA to take 10-20 years to approve a new drug which could drastically help us!
New research has began to prove that commonly used diabetes drug, shows promise in reducing intracranial pressure (ICP) in patients with idiopathic intracranial hypertension (IIH) and other conditions associated with elevated brain pressure. Researchers at the University of Birmingham, United Kingdom, studied the effect of exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist (RA), in rats with elevated ICP.
In fact, researchers found that the GLP-1 agonist medication reduced ICP by 44% within 10 minutes of dosing. Moreover, the treatment effects lasted at least 24 hours!!! Patients in IIH groups in Facebook who take GLP-1 agonist medication say this medication helps them with their disease more than anything else. These drugs have already been approved and have been proven safe by the FDA and many type 2 diabetes patients use this medication. Why can't we? This is a medication that IIH patients NEED and one that WE NEED NOW.
In fact, only recently has Diamox received clinical findings via studies which are leading towards providing evidence of its capability to lower CSF. Yet, this medication has been given to IIH patients for decades OFF-LABEL. Could you imagine where some of us would be without even having Diamox as an option, and if we had waited to use Diamox until it wasn't used off-label? (http://www.eyecenter.emory.edu/emory-eye/neuroop-intracranial.shtml)
Our eyesight and health is in jeopardy. GLP-1 agonist medication can safely reduce ICP by 44% within 10 minutes of dosing for IIH patients. This is a more powerful medication for people with IIH than Diamox or Topomax ever has been. By making this medication readily available, the FDA could save many patients from needing surgery and lower mortality rates for patients with IIH.
Make the FDA approve GLP-1 agonist medication for patients with IIH NOW by signing your name in this petition.
Today: Leah is counting on you
Leah Harris needs your help with “Make the FDA approve GLP-1 receptor agonist medications for patients with Idiopathic Intracranial Hypertension--NOW!”. Join Leah and 542 supporters today.